{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fuche FJ"],"funding":["NIAID NIH HHS"],"pagination":["1427-1435"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6663134"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(6)"],"pubmed_abstract":["Non-typhoidal <i>Salmonella</i> (NTS) are a leading cause of foodborne infections worldwide, and serogroups B, C<sub>1</sub>, C<sub>2-</sub>C<sub>3</sub> and D are the most common serogroups associated with human disease. While live vaccine candidates that protect against <i>S.</i> Typhimurium (serogroup B) and <i>S.</i> Enteritidis (serogroup D) have been described by us and others, far less effort has been directed towards vaccines that target either serogroup C<sub>1</sub> or C<sub>2-</sub>C<sub>3</sub> <i>Salmonella</i>. Here we describe a <i>Salmonella</i> Newport-based live-attenuated vaccine (serogroup C<sub>2-</sub>C<sub>3</sub>). Deletion of the genes <i>clpX</i> or <i>rfaL</i>, previously used in live vaccines to attenuate <i>S.</i> Typhimurium and/or <i>S.</i> Enteritidis, faile"],"journal":["Human vaccines & immunotherapeutics"],"pubmed_title":["Deletions in <i>guaBA</i> and <i>htrA</i> but not <i>clpX</i> or <i>rfaL</i> constitute a live-attenuated vaccine strain of <i>Salmonella</i> Newport to protect against serogroup C<sub>2-</sub>C<sub>3</sub> <i>Salmonella</i> in mice."],"pmcid":["PMC6663134"],"funding_grant_id":["U19 AI109776"],"pubmed_authors":["Fuche FJ","Ramachandran G","Jones JA","Tennant SM","Higginson EE","Simon R"],"additional_accession":[]},"is_claimable":false,"name":"Deletions in <i>guaBA</i> and <i>htrA</i> but not <i>clpX</i> or <i>rfaL</i> constitute a live-attenuated vaccine strain of <i>Salmonella</i> Newport to protect against serogroup C<sub>2-</sub>C<sub>3</sub> <i>Salmonella</i> in mice.","description":"Non-typhoidal <i>Salmonella</i> (NTS) are a leading cause of foodborne infections worldwide, and serogroups B, C<sub>1</sub>, C<sub>2-</sub>C<sub>3</sub> and D are the most common serogroups associated with human disease. While live vaccine candidates that protect against <i>S.</i> Typhimurium (serogroup B) and <i>S.</i> Enteritidis (serogroup D) have been described by us and others, far less effort has been directed towards vaccines that target either serogroup C<sub>1</sub> or C<sub>2-</sub>C<sub>3</sub> <i>Salmonella</i>. Here we describe a <i>Salmonella</i> Newport-based live-attenuated vaccine (serogroup C<sub>2-</sub>C<sub>3</sub>). Deletion of the genes <i>clpX</i> or <i>rfaL</i>, previously used in live vaccines to attenuate <i>S.</i> Typhimurium and/or <i>S.</i> Enteritidis, faile","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2025-04-04T11:43:12.057Z","creation":"2019-08-09T07:03:55Z"},"accession":"S-EPMC6663134","cross_references":{"pubmed":["29927725"],"doi":["10.1080/21645515.2018.1491499"]}}